<p>DAWNRAYS PHARMA (02348.HK) announced its interim results for the six months ending in June, with revenue of RMB 630 million, a year-on-year decrease of 9.2%. It recorded a net profit of RMB 105 million, a decline of 78.8%, with earnings per share of 6.961 cents. The interim dividend remains at 1.5 Hong Kong cents</p>

02348

<p>DAWNRAYS PHARMA announced its interim results for the six months ended June, with revenue of RMB 630 million, a year-on-year decrease of 9.2%. It recorded a net profit of RMB 105 million, a decline of 78.8%, with earnings per share of 6.961 cents. The interim dividend remains at 1.5 HK cents</p>

《业绩》东瑞制药中期纯利 1.05 亿人民币跌 78.8% 派息 1.5 港仙